Expanded Access to RXDX-105 for Cancers With RET Alterations

Cancers With RET Alterations Clinical Trial

Official title:

Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT03052569
• Other study ID #: RXDX-105 - EAP
• Status: No longer available

Study information

• Verified date: April 2019
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of advanced cancer with RET alterations

• Unable to participate in an ongoing RXDX-105 clinical trial

• Willing and able to provide written, signed informed consent

• Medically suitable for treatment with RXDX-105

Exclusion Criteria:

• Prior treatment with a TKI that has activity against RET alterations

• Currently enrolled in an ongoing clinical study with any other investigational agent

Related Conditions & MeSH terms

• Cancers With RET Alterations

Intervention

Drug:
• RXDX-105
Oral Capsules

Locations

Country	Name	City	State
United States	Www.Ignyta.Com	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States,